The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Comparing experiences of patients with SCD in developed and developing countries: UK versus India
Sanne Lugthart, MD, PhD, University Hospitals of Bristol and Weston NHS Foundation Trust, Bristol, UK, discusses a comparison of patient experiences with sickle cell disease (SCD) in developed and developing countries, highlighting differences in physiological measures and patient-reported outcomes (PROs) between patient cohorts from the United Kingdom and Indian. Dr Lugthart notes that the UK cohort had higher levels of symptom severity, while the Indian cohort had a higher EQ-5D score. She emphasizes the need to explore the underlying causes of these differences, including environmental and healthcare system factors. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
